Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
Cureus ; 14(10): e30939, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-2309069

ABSTRACT

Hyponatremia is a common complication in COVID-19-positive patients and is associated with significant mortality and morbidity. Several cases of COVID-19-related hyponatremia secondary to the Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) have been reported in the literature, which might suggest that SIADH is almost always the underlying cause of hyponatremia in COVID-19 infections. However, COVID-19-related hyponatremia can have diverse underlying etiologies, similar to hyponatremia in non-COVID-19 patients, and requires a thorough assessment to reach a correct diagnosis and implement appropriate management.

2.
Eur J Case Rep Intern Med ; 7(10): 001905, 2020.
Article in English | MEDLINE | ID: covidwho-2279434

ABSTRACT

Coronavirus disease 2019 (COVID-19) was first reported in Wuhan, China, in December 2019. The disease is caused by severe acute respiratory syndrome virus coronavirus 2 (SARS-CoV-2). A few published cases have linked COVID-19 and hyponatremia. The mechanism of hyponatremia in these cases is related to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Here we present a unique case of urinary retention and SIADH as unusual presenting features of SARS-CoV-2 infection. LEARNING POINTS: Urine retention could be an unusual presenting symptom of severe hyponatremia of COVID-19.Hyponatremia and SIADH could be unusual presenting features of SARS-CoV-2 infection.Careful correction of hyponatremia related to COVID-19 is necessary to avoid osmotic demyelination syndrome.

3.
J R Coll Physicians Edinb ; 53(2): 111-113, 2023 Jun.
Article in English | MEDLINE | ID: covidwho-2255914

ABSTRACT

A 31-year-old female presented to the emergency department with abdominal pain, vomiting and constipation. Serum sodium levels were recorded at 110 mmol/L on admission, dropping to 96 mmol/L despite fluid restriction. The patient developed hallucinations and required hypertonic saline administration in critical care. Urinary sodium was detected at 149 mmol/L, consistent with syndrome of inappropriate antidiuretic hormone secretion (SiADH). Urinary porphyrins were also raised, consistent with a diagnosis of acute intermittent porphyria with SiADH as a complication.


Subject(s)
Inappropriate ADH Syndrome , Porphyria, Acute Intermittent , Female , Humans , Adult , Inappropriate ADH Syndrome/diagnosis , Inappropriate ADH Syndrome/etiology , Porphyria, Acute Intermittent/complications , Porphyria, Acute Intermittent/diagnosis , Abdominal Pain/etiology , Vasopressins , Sodium
4.
Cureus ; 15(1): e34161, 2023 Jan.
Article in English | MEDLINE | ID: covidwho-2250643

ABSTRACT

Hyponatremia is one of the common electrolyte imbalances among hospitalized patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) being a common etiology for hyponatremia. There are multiple pathophysiologic considerations in the differential diagnosis of the etiologic factor for SIADH, including infections such as pneumonia and meningitis, as well as coronavirus disease 2019 (COVID-19) infection. However, SIADH, as the sole initial presentation of the infection of COVID-19, is rarely reported. In this report, we present a case of SIADH as the initial and only presentation of a COVID-19 infection, highlighting the clinical course and treatment strategy while providing the putative pathophysiologic insights into this unusual and potentially serious complication of COVID-19 infection.

5.
IDCases ; 31: e01688, 2023.
Article in English | MEDLINE | ID: covidwho-2179288

ABSTRACT

Background: Severe hyponatraemia can lead to serious neurological complications including coma, seizure and death. Hyponatraemia and the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) has been previously described in cases of COVID-19, however there have been few reports post vaccination. We describe a case of severe hyponatraemia post second Pfizer BNT162b2 mRNA vaccination against COVID-19. Case presentation: A 48-year-old previously well woman presented to the emergency department with severe headaches and confusion one day after she received her second Pfizer COVID-19 vaccination. She reported no more than 2.5 L fluid intake. Vital signs were normal. Laboratory investigation revealed serum sodium 113 mmol/L, potassium 3.4 mmol/L, urea 3.5 mmol/L and serum osmolality 266 mmol/kg. TSH, random cortisol and C-reactive protein levels were normal. She was found to be in urinary retention and developed marked polyuria post in dwelling catheter insertion. Following this she underwent spontaneous and rapid correction of serum sodium without intervention. Retrospective analysis showed an inappropriately high copeptin of 4.4 pmol/L. Conclusions: It is important to be cautioned and aware of hyponatraemia as an immediate side effect of COVID-19 vaccination. The exact mechanism is unknown and further research is required to understand the acute endocrine effects which may arise in response to COVID-19 vaccination.

6.
Pamukkale Medical Journal ; 14(3):768-773, 2021.
Article in Turkish | ProQuest Central | ID: covidwho-1965063

ABSTRACT

Uygunsuz antidiüretik hormon salınım sendromu (UADHSS), hastanede yatan hastalarda hiponatreminin en sık nedenlerinden biridir. Hiponatreminin etiyolojisinde birçok neden olmasından dolayı sebebinin bulunup tedavi edilmesinde güçlük yaşanabilmektedir. UADHSS’a neden olabilecek birçok infeksiyon hastalığı bildirilmiştir. Bununla birlikte Koronavirüs 2019 hastalığı (COVID-19) ile ilişkili hiponatremi ve UADHSS son zamanlarda birkaç olgu raporunda belirtilmiştir. Bizim olgumuzda ise ilk hastaneye başvuru sırasında COVID-19 pnömonisinin klasik semptomları olan öksürük, nefes darlığı ve ateş şikayeti, ikinci başvurusunda ise hiponatreminin klinik semptomlarından olan halsizlik, genel durum bozukluğu görülmekteydi. COVID-19 olan bir hastada hiponatremi ve UADHSS’nın görülebileceğini vurgulamayı amaçladık.Alternate :Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is one of the most common causes of hyponatremia in hospitalized patients. Since there are several etiologies of hyponatremia, it may be difficult to identify and treat the etiology. Several infectious diseases have been reported to cause SIADH. However, hyponatremia and SIADH induced by Coronavirus 2019 disease (COVID-19) have been reported in several recent case reports. However, our case admitted to hospital with the classic symptoms of COVID-19 pneumonia including cough, dyspnea and fever at his first admission, and with the clinical symptoms of hyponatremia, including weakness and general condition disorderat his second admission. Our aim is to emphasize that hyponatremia and SIADHmay be observed in our COVID-19 patient.

7.
Egyptian Journal of Hospital Medicine ; 88(1):3293-3298, 2022.
Article in English | Scopus | ID: covidwho-1964931

ABSTRACT

Background: Coronavirus disease 2019 (COVID-19) is frequently associated with hyponatremia. Individuals with history of chronic kidney disease (CKD) are more likely to experience critical complications related to COVID-19. Objective: This study aimed to identify the prevalence and outcomes of admittance of hyponatremia in COVID-19 patients with history of CKD. Patients and Methods: The study involved admitted CKD patients with COVID-19 between January 2021 and April 2021. It was performed at Zagazig University hospital. Subjects were divided according to admittance serum sodium into group 1 with hyponatremia (80 subjects) and group 2 with normonatremia (68 subjects). Hypernatremic patients were excluded. Clinical and laboratory data were collected from all subjects. Patients were observed for the occurrence of acute respiratory failure, and acute renal failure. Additionally, mortality rates were recorded. Results: Patients in group 1 stayed longer in the hospital than in group 2 (p = 0.034). Additionally, they had higher systolic blood pressure records (p < 0.001). Group 1 had significantly shorter survival and higher incidence rates of acute kidney injury (AKI) than group 2. Finally, multivariate analysis revealed that the significant risk factors for in-hospital mortality in group 1 were older age, longer hospital stay, higher serum potassium, and higher LDH. Conclusion: In our study, hyponatremia affected 54% of CKD patients with COVID-19 and was attributed to higher rates of AKI and in-hospital mortality. © 2022, Ain Shams University Faculty of Medicine. All rights reserved.

8.
J Community Hosp Intern Med Perspect ; 11(6): 779-781, 2021.
Article in English | MEDLINE | ID: covidwho-1532370

ABSTRACT

COVID-19, also known as SARS-CoV-2, which originated in China in late 2019, has spread rapidly resulting in a global pandemic. COVID-19 has been linked to many different clinical manifestations, including hyponatremia. The cause of hyponatremia in acute COVID-19 infection is speculated to be multifactorial, including syndrome of inappropriate antidiuretic hormone secretion (SIADH), thought to be a result of inflammatory cytokines (Interleukin-6) and/or related to the gastrointestinal symptoms of this infection. SIADH in the setting of COVID-19 pneumonia is an established complication of this disease. This is the case of an 81-year-old woman with a history of hypertension, on thiazide diuretic, initially presented after a fall in the setting of COVID-19 pneumonia. She was treated with remdesivir and dexamethasone and then discharged to a rehab facility with normal labwork, including a sodium of 137 mmol/L. Two weeks later, routine labwork identified hyponatremia of 111 mmol/L. Her vital signs were normal, she was euvolemic on exam and alert/oriented with no complaints. Investigations into the etiology of her hyponatremia included a urine sodium of 72 mmol/L, serum osmolality of 231 mOsm/kg, urine osmolality of 454 mOsm/kg. We diagnosed hypo-osmolar hyponatremia due to SIADH. Management included fluid restriction and then tolvaptan, which ultimately corrected the serum sodium to 134 mmol/L. As COVID-19 is a new infection, little is known regarding its impact on electrolyte imbalances. Our patient recovered from pneumonia, then later developed severe hyponatremia possibly secondary to the lasting effects of inflammation in her lungs.

9.
Clin Case Rep ; 9(10): e04667, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1469426

ABSTRACT

In a system already preconditioned by previous damage, as results of the cytokine release syndrome complicating the COVID-19 disease, a small trigger may be sufficient to develop a SIADH complicating a GBS, even without a poor outcome.

10.
BMC Infect Dis ; 21(1): 1000, 2021 Sep 25.
Article in English | MEDLINE | ID: covidwho-1438261

ABSTRACT

BACKGROUND: The Syndrome of Inappropriate Antidiuresis (SIADH) has been described to be associated with a multitude of conditions and medications, including the severe acute respiratory syndrome coronavirus 2. We describe the case of a patient with newly diagnosed and symptomatic SIADH after receiving the second COVID-19 vaccination not explained otherwise. CASE PRESENTATION: A 79-year-old male person was admitted to the emergency department due to a worsening of his general health state expressed by weakness, fatigue and anorexia. Vital signs and clinical findings were normal, in particular the patient was considered to be euvolemic. Laboratory investigations revealed a serum sodium of 117 mmol/L, a serum osmolality of 241 mosm/kg and a urea of 1.2 mmol/L with creatinine within normal range. Urine chemistry showed a urine osmolality of 412 mosm/kg and urine sodium of 110 mmol/L. TSH, C-reactive protein, and basal cortisol levels were normal. Under therapy with balanced crystalloid fluids, hyponatremia worsened and in absence of diuretic medications, diagnosis of SIADH was made. Since fluid restriction was not sufficiently effective, oral urea was administered. Under this therapy regimen hyponatremia resolved. CONCLUSIONS: Local as well as systemic reactions have been described for the new mRNA-based vaccines including pain and fever. Therefore, it is imaginable that the vaccine might trigger SIADH in some patients.


Subject(s)
COVID-19 , Hyponatremia , Inappropriate ADH Syndrome , Aged , COVID-19 Vaccines , Humans , Hyponatremia/etiology , Inappropriate ADH Syndrome/chemically induced , Male , SARS-CoV-2 , Vaccination
11.
Cureus ; 13(7): e16671, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1350529

ABSTRACT

Various electrolyte imbalances have been documented in coronavirus disease 2019 (COVID-19) patients who progress to severe acute respiratory syndrome coronavirus-2 infection. Patients with co-morbidities like diabetes, hypertension, obesity, ischemic heart disease, chronic kidney disease, and chronic obstructive pulmonary disease are more vulnerable to developing complications in the form of electrolyte disturbance. We report a case of acute severe hyponatremia in a middle-aged man who was admitted to the hospital with viral pneumonia due to a coronavirus-2 infection. A dramatic drop of plasma sodium was preceded by gastrointestinal symptoms and followed by encephalopathy. On clinical assessment his plasma sodium was found to be critically low, i.e. 105 mmol/L. His chest x-ray showed minimal pleural effusion. The patient was managed in the ICU and his serum sodium was normalized gradually with partial but rapid correction of this severe hyponatremia with hypertonic sodium chloride and followed by fluid restriction.

12.
Cureus ; 13(6): e15603, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1285554

ABSTRACT

Coronavirus disease 2019 (COVID-19) is a widespread disease. Hyponatremia in the setting of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) was described with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Nonetheless, seizure as a prominent manifestation of hyponatremia associated with COVID-19 is rare. We present a case of a middle-aged man with mild COVID-19 pneumonia, who developed a seizure due to SIADH-related severe hyponatremia.

13.
BMC Infect Dis ; 21(1): 465, 2021 May 21.
Article in English | MEDLINE | ID: covidwho-1238707

ABSTRACT

BACKGROUND: Coronavirus Disease-2019 (COVID-19) has been declared a global pandemic since March 11th, 2020. Despite emerging reports and literature covering a broad spectrum of COVID-19 clinical manifestations, facets of COVID-19 have not been fully elucidated. To the authors' concern, sinus bradycardia as a manifestation of COVID-19-induced syndrome of inappropriate antidiuretic hormone (SIADH) has never been reported before. CASE PRESENTATION: In this paper, we report a case of a 59-year-old male patient with confirmed COVID-19 initially presented with presyncope. Further investigations reveal sinus bradycardia related to COVID-19-induced SIADH. This case highlights the possibility of immuno-neuroendocrino-cardiovascular crosstalk resulting in an atypical manifestation of COVID-19: near syncope due to sinus bradycardia. CONCLUSIONS: Another possible cause of sinus bradycardia in COVID-19 is electrolyte imbalance due to COVID-19-related SIADH.


Subject(s)
Bradycardia/diagnosis , COVID-19/diagnosis , Inappropriate ADH Syndrome/diagnosis , SARS-CoV-2 , Bradycardia/complications , Bradycardia/physiopathology , COVID-19/complications , Diagnosis, Differential , Electrocardiography , Humans , Inappropriate ADH Syndrome/complications , Male , Middle Aged , Water-Electrolyte Balance
14.
Pituitary ; 24(3): 465-481, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1210726

ABSTRACT

BACKGROUND: Despite COVID-19 being identified as severe respiratory viral infection, progressively many relevant endocrine manifestations have been reported greatly contributing to the severity of the clinical presentation. Systemic involvement in COVID-19 is due to the ubiquitous expression of angiotensin-converting enzyme 2 (ACE2) receptor, responsible for the entry in the cells of SARS-CoV-2, Several reports in humans and animal models showed a significant ACE2 mRNA expression in hypothalamus and pituitary cells. Moreover, higher mortality and poorer outcomes have been widely described in COVID-19 patients with obesity, diabetes and vertebral fractures, which are all highly prevalent in subjects with pituitary dysfunctions. AIM: To review the main endocrine manifestations of COVID-19 with their possible implications for pituitary diseases, the possible direct and indirect involvement of the pituitary gland in COVID-19, the impact of COVID-19 on the management of established pituitary diseases which can be already at increased risk for worse outcomes and on neurosurgical activities as well as vaccination. CONCLUSIONS: Our review underlines that there could be a specific involvement of the pituitary gland which fits into a progressively shaping endocrine phenotype of COVID-19. Moreover, the care for pituitary diseases need to continue despite the restrictions due to the emergency. Several pituitary diseases, such as hypopituitarism and Cushing disease, or due to frequent comorbidities such as diabetes may be a risk factor for severe COVID-19 in affected patients. There is the urgent need to collect in international multicentric efforts data on all these aspects of the pituitary involvement in the pandemic in order to issue evidence driven recommendations for the management of pituitary patients in the persistent COVID-19 emergency.


Subject(s)
COVID-19/virology , Pituitary Diseases/virology , Pituitary Gland/virology , SARS-CoV-2/pathogenicity , Angiotensin-Converting Enzyme 2/metabolism , Animals , COVID-19/epidemiology , COVID-19/physiopathology , COVID-19/therapy , Comorbidity , Host-Pathogen Interactions , Humans , Pituitary Diseases/epidemiology , Pituitary Diseases/physiopathology , Pituitary Diseases/therapy , Pituitary Gland/metabolism , Pituitary Gland/physiopathology , Prognosis , Receptors, Virus/metabolism , Risk Assessment , Risk Factors , Virus Internalization
16.
Medicina (Kaunas) ; 57(1)2021 Jan 09.
Article in English | MEDLINE | ID: covidwho-1016197

ABSTRACT

Nowadays, humanity faces one of the most serious health crises, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The severity of coronavirus disease 2019 (COVID-19) pandemic is related to the high rate of interhuman transmission of the virus, variability of clinical presentation, and the absence of specific therapeutic methods. COVID-19 can manifest with non-specific symptoms and signs, especially among the elderly. In some cases, the clinical manifestations of hyponatremia may be the first to appear. The pathophysiological mechanisms of hyponatremia among patients with COVID-19 are diverse, including syndrome of inappropriate antidiuretic hormone secretion (SIADH), digestive loss of sodium ions, reduced sodium ion intake or use of diuretic therapy. Hyponatremia may also be considered a negative prognostic factor in patients diagnosed with COVID-19. We need further studies to evaluate the etiology and therapeutic management of hyponatremia in patients with COVID-19.


Subject(s)
COVID-19/metabolism , Hyponatremia/metabolism , Inappropriate ADH Syndrome/metabolism , COVID-19/complications , Diuretics/adverse effects , Fluid Therapy/methods , Humans , Hyponatremia/epidemiology , Hyponatremia/etiology , Hyponatremia/therapy , Inappropriate ADH Syndrome/etiology , Incidence , Interleukin-6/metabolism , Intestinal Mucosa/metabolism , Prognosis , SARS-CoV-2 , Saline Solution, Hypertonic/therapeutic use , Sodium, Dietary
17.
Respir Med Case Rep ; 31: 101290, 2020.
Article in English | MEDLINE | ID: covidwho-919529

ABSTRACT

BACKGOUND: Novel corona virus(SARS-CoV-2) which emerged from Wuhan, China, has spread to whole worlds very rapidly causing enormous health effect and death. Current publications worldwide showed that COVID-19 is a disease involving multiple system of the body with many unusual presentations. So physicians face the challenges to manage it in the hospital. CASE REPORT: The syndrome of inappropriate secretion of anti diuretic hormone (SIADH) is one of the most common causes of hyponatremia accounts for approximately one-third of all cases. In the diagnosis of SIADH it is important to ascertain the euvolemic state of extra cellular fluid volume, both clinically and laboratory measurement. Several infections associated with SIADH have been reported. Howover, Coronavirus disease 2019(COVID-19) associated with SIADH were only few cases reported. We are presenting a case of 70 year old female admitted with unconsciousness later diagnosed as severe hyponatremia along with COVID-19 complicated with severe pneumonia.

18.
Cureus ; 12(6): e8841, 2020 Jun 26.
Article in English | MEDLINE | ID: covidwho-696682

ABSTRACT

Syndrome of inappropriate antidiuretic hormone (SIADH) is the leading cause of hyponatremia. We, herein, report a case of a patient with coronavirus disease-2019 (COVID-19) who developed sudden exertional dyspnea and hypoxia and was found to be hyponatremic. A diagnosis of SIADH was made due to COVID-19 pneumonia. The patient was managed conservatively with a significant improvement during the course of hospitalization and on follow-up.

19.
Clin Kidney J ; 13(3): 274-280, 2020 Jun.
Article in English | MEDLINE | ID: covidwho-663076

ABSTRACT

COVID-19 is a global pandemic fuelled in some countries by government actions. The current issue of Clinical Kidney Journal presents 15 articles on COVID-19 and kidney disease from three continents, providing a global perspective of the impact of severe acute respiratory syndrome coronavirus 2 on electrolytes and different kidney compartments (glomeruli, tubules and vascular compartments) and presenting clinically as a syndrome of inappropriate antidiuretic hormone secretion, acute kidney injury, acute kidney disease, collapsing glomerulopathy and thrombotic microangiopathy, among others, in the context of a brand-new cardiorenal syndrome. Kidney injury may need acute dialysis that may overwhelm haemodialysis (HD) and haemofiltration capabilities. In this regard, acute peritoneal dialysis (PD) may be lifesaving. Additionally, pre-existent chronic kidney disease increases the risk of more severe COVID-19 complications. The impact of COVID-19 on PD and HD patients is also discussed, with emphasis on preventive measures. Finally, current therapeutic approaches and potential future therapeutic approaches undergoing clinical trials, such as complement targeting by eculizumab, are also presented.

20.
Acta Endocrinol (Buchar) ; 16(1): 110-111, 2020.
Article in English | MEDLINE | ID: covidwho-655414

ABSTRACT

At the end of 2019, a novel coronavirus was identified as the cause of a cluster of pneumonia in China and it spread quickly to other countries. Although Covid-19 causes severe pneumonia, it is known that it can be associated with different diseases and prognosis of disease can be due to many of disorders such as hyponatremia. A 65-year-old female patient with sarcoidosis, cronic obstructive lung disease, hypertension and congestive heart failure presented to the emergency department with shortness of breath and fever. Oropharyngeal swab for Covid-19 PCR test was positive. After the initiation of treatment, the patient developed hyponatremia. This case is remarkable because there is no reported case of Covid-19 and inappropriate ADH syndrome coexistence and it demonstrates that there may be a correlation between Covid-19 infection prognosis and hyponatremia.

SELECTION OF CITATIONS
SEARCH DETAIL